Related Experiment Video
Updated: Aug 12, 2026
08:31
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
11.1K
Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery
Roy van der Meel1,2,3, Sam Chen2,4, Josh Zaifman4,5
1Laboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.
Small (Weinheim an Der Bergstrasse, Germany)
|August 2, 2021
Summary
This study shows lipid nanoparticles (LNPs) can combine gene silencing and chemotherapy for enhanced cancer treatment. Co-encapsulating siRNA and prodrugs in LNPs offers a versatile platform for combination therapy development.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- Efficient intracellular delivery of small interfering RNA (siRNA) therapeutics necessitates nanotechnology.
- Lipid nanoparticles (LNPs) are a proven platform for nucleic acid therapeutics, offering modularity and enabling combination therapies through co-encapsulation of multiple agents.
- Drug derivatization allows synthesis of lipophilic small molecule prodrugs for stable incorporation into LNPs.
Purpose of the Study:
- To investigate the application of a modular LNP platform for combined gene silencing and chemotherapy to achieve additive anticancer effects.
- To demonstrate the co-encapsulation of lipophilic taxane prodrug derivatives and siRNA targeting the androgen receptor within LNPs.
- To evaluate the therapeutic efficacy and pharmacokinetic properties of this combined LNP formulation.
Main Methods:
- Co-encapsulation of lipophilic taxane prodrug derivatives and siRNA against the androgen receptor in LNPs.
- Assessment of physicochemical properties and gene-silencing ability of the co-encapsulated LNPs.
- In vitro evaluation of combination therapy effects.
- Quantitative determination of pharmacokinetic properties and biodistribution in tumor-bearing mice using a double-radiolabeling approach.
Main Results:
- Lipophilic taxane prodrug derivatives and siRNA were efficiently and stably co-encapsulated in LNPs without compromising properties or gene-silencing efficacy.
- The combination therapy demonstrated additive therapeutic effects in vitro.
- Pharmacokinetic and biodistribution studies in mice confirmed the stability and distribution of co-encapsulated agents.
Conclusions:
- Co-encapsulating siRNA and lipophilic prodrugs into LNPs is a viable and straightforward plug-and-play approach for developing combination therapies.
- This LNP platform facilitates the development of novel anticancer treatments by combining gene silencing and chemotherapy.
- The modularity of LNPs supports the creation of advanced combination therapies for improved therapeutic outcomes.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...